On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of o'pka saratoni conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes shish cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibbning ma'lum qilishicha, kompaniya Opdivoning o'pka saratoni ko'rsatkichlarini davolash uchun arizasini FDA va Evropa Ittifoqi farmatsevtika ma'muriyatiga topshirgan. Albatta, shuhratparast Squibb kompaniyasi tabiiy ravishda nafaqat o'pka saratoni va melanoma bilan qoniqmaydi. Aslida, Squibb hozirda Opdivo bo'yicha 35 dan ortiq tadqiqotlarni o'tkazmoqda yoki turli xil o'sma turlarini davolash uchun boshqa dorilar bilan birgalikda. Tahlilchilarning fikriga ko'ra, Opdivoning kelajakdagi savdosi 5 milliard AQSh dollariga etadi.
The cancer immunoterapiya research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Ingliz tilidagi batafsil hisobot:
O'tgan oyda Opdivo nomi bilan tasdiqlangan Bristol-Myers Squibb ($ BMY) nivolumab immuno-nokologik dori-darmonlari o'pka saratoni bo'yicha so'nggi bosqichda sinovdan o'tkazilib, kashshof davolashni sotish bo'yicha umidlarni kuchaytirdi.
272 bemor ishtirokida o'tkazilgan tadqiqotda Opdivo-ni saraton kasalligini o'ldiradigan standart dosetaksel bilan solishtirganda, Bristol-Myers preparati nazorat qiluvchi qo'l bilan solishtirganda shunchalik yuqori umumiy omon qolish qobiliyatini namoyish etdiki, u o'zining asosiy yakuniy nuqtasiga muddatidan oldin etib keldi va sinov ma'lumotlarini nazorat qilish qo'mitasi tavsiya qildi. o'qish muddatidan oldin tugatilishi kerak. Bristol-Myers endi dosetaksel guruhidagi bemorlarni ochiq yorliqli kengaytmali tadqiqot orqali Opdivo-ga kirishga taklif qilmoqda.
Bristol-Myersning davolashi PD-1 deb nomlangan yo'lni to'sib qo'yish orqali o'smalarga qarshi immun tizimining hujumini kuchaytirish uchun mo'ljallangan, bu nazoratsiz qoldirilgan saraton hujayralari tananing tabiiy himoyasi bilan aniqlanmasdan o'tishiga imkon beradi. Merck's ($ MRK) shunga o'xshash Keytruda singari, Opdivo o'tgan yili melanomani davolash sifatida FDA ma'qulligini qo'lga kiritdi, ammo Bristol-Myers preparati o'pka saratonida yolg'iz turadi, chunki uning so'nggi klinik muvaffaqiyati PD-1 inhibitori birinchi marta o'pka saratonini aniqladi. kasallikdan omon qolish afzalligi, kompaniya dedi.
Opdivo’s particular promise in kichik hujayrali o'pka saratoni has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers AQSh va Evropada o'pka saratoni uchun Opdivo uchun o'pka saratoni bo'yicha arizalarni topshirdi va bu yil oxirida preparatni qo'llashni kengaytirishni kutmoqda.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, bosh va bo'yin saratoni, glioblastoma, Non-Hodgkin lymphoma and other cancers.
